Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.

about

Isoviolanthin Extracted from Dendrobium officinale Reverses TGF-β1-Mediated Epithelial⁻Mesenchymal Transition in Hepatocellular Carcinoma Cells via Deactivating the TGF-β/Smad and PI3K/Akt/mTOR Signaling Pathways.

P2860

Q55625598-B1584C76-7229-4868-BC13-97F031B3C90C

P2860

Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.

Item

http://www.wikidata.org/entity/Q48266660

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Oral oxycodone/naloxone for pa ...... atic hepatocellular carcinoma.

@en

Oral oxycodone/naloxone for pa ...... atic hepatocellular carcinoma.

@nl

type

Item

label

Oral oxycodone/naloxone for pa ...... atic hepatocellular carcinoma.

@en

Oral oxycodone/naloxone for pa ...... atic hepatocellular carcinoma.

@nl

prefLabel

Oral oxycodone/naloxone for pa ...... atic hepatocellular carcinoma.

@en

Oral oxycodone/naloxone for pa ...... atic hepatocellular carcinoma.

@nl

P1476

Oral oxycodone/naloxone for pa ...... tatic hepatocellular carcinoma

@en

P2093

Francesca Benevento

http://www.w3.org/2001/XMLSchema#string

Stefania De Lorenzo

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

Pain management in the cirrhotic patient: the clinical challenge.

Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.

The past, present, and future of cancer incidence in the United States: 1975 through 2020

Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.

Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis

The global impact of hepatic fibrosis and end-stage liver disease.

Combined oral prolonged-release oxycodone and naloxone in chronic pain management.

Analgesia for the cirrhotic patient: a literature review and recommendations.

The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations

P304

278-284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.13546

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fabio Piscaglia

F Tovoli

Boaz G Samolsky Dekel

Giovanni Brandi

Luigi Bolondi

P577

2017-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28792650

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.

about

P2860

P2860

Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921